 |
14 Diseases |  |
0 Trials |
|
0 Trials |  |
25 News |  |
- || Review, Journal: IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. (Pubmed Central) - Apr 18, 2023
An
- ||| Review, Journal, Adverse events: Adverse Effects of Anti-Interleukin-23 Agents Employed in Patients with Psoriasis: A Systematic Review. (Pubmed Central) - Sep 10, 2022
Over the last 3 years, ustekinumab, guselkumab, tildrakizumab, and risankizumab have successively come to the market. However, these drugs caused several immunological and nonimmunological side effects, but they are customarily well-tolerated and have orderly safety vignettes.
- INTERLEUKIN-23 AND INTERLEUKIN-12/23 INHIBITORS FOR THE TREATMENT OF CROHN’S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS (Science Lounge) - Jul 20, 2022 - Abstract #UEGW2022UEGW_1916;
All studies except two were placebo-controlled; in these studies, two active agents (UST vs. adalimumab) and two doses of the same agent (UST) were evaluated, respectively... Drugs targeting IL-23 are effective for inducing and maintaining clinical remission in patients with moderate-to-severe CD.
- || Clinical, Journal: Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say? (Pubmed Central) - Jan 14, 2022
The safety evidence from RCTs on the p19 inhibitors are reassuring thus far, but these studies may not detect rare CV events in real-world patients. We concluded that the overall evidence does not show that ustekinumab is associated with an increase in the risk of CV disease in patients with psoriasis, but further data are awaited to assess the CV safety of p19 inhibitors for the treatment of psoriasis.
- || Entyvio (vedolizumab) / Takeda
Review, Journal: Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More. (Pubmed Central) - Aug 20, 2021
Key messages: New IBD treatments are successful for a significant fraction of patients. However, new strategies for patient selection, treatment combinations, and/or additional therapies must be developed to serve the need of all IBD patients.
- Orencia (abatacept) / BMS, Stelara (ustekinumab) / J&J
[VIRTUAL] GENOME-WIDE META-ANALYSIS OF PRIMARY BILIARY CHOLANGITIS IDENTIFIES 21 ADDITIONAL RISK LOCI AND PRIORITISES DRUG CANDIDATES POTENTIALLY SUITABLE FOR RE-PURPOSING () - Oct 11, 2020 - Abstract #AASLD2020AASLD_14;
However, new strategies for patient selection, treatment combinations, and/or additional therapies must be developed to serve the need of all IBD patients. This study provides a hierarchy of agents that could be trialled in PBC, and emphasises the value of genetic and genomic approaches to drug discovery in complex disorders.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Review, Journal: Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. (Pubmed Central) - May 1, 2020
This review will be updated when the results of this study become available. The manufacturers of briakinumab have stopped production of this medication, thus further studies of briakinumab are unlikely.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J
Retrospective data, Journal: Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis. (Pubmed Central) - Jan 4, 2020
Brodalumab present very good potential in efficacy outcome like PASI and PGA. More clinical trials are required to supply more data about discontinuation of infliximab and infection of brodalumab and larger RCT for assessment of briakinumab.
- |||| Ozespa (briakinumab) / AbbVie
Trial completion: Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Feb 22, 2014
P2, N=215, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
More clinical trials are required to supply more data about discontinuation of infliximab and infection of brodalumab and larger RCT for assessment of briakinumab. Active, not recruiting --> Completed
- ||||||| Ozespa (briakinumab) / AbbVie
Trial completion: Open Label Continuation Study in Moderate to Severe Psoriasis (clinicaltrials.gov) - Dec 19, 2011
P3, N=2301, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Ozespa (briakinumab) / AbbVie
Trial withdrawal: Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates. (clinicaltrials.gov) - Oct 19, 2011
P1, N=12, Withdrawn, Sponsor: Abbott
Active, not recruiting --> Completed Terminated --> Withdrawn